Welcome to our dedicated page for CATALENT news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on CATALENT stock.
Catalent, Inc. (symbol: CTLT) is a leading contract development and manufacturing organization (CDMO) that plays a crucial role in the global pharmaceutical and biotechnology industries. With over 80 years of experience, Catalent specializes in providing a comprehensive range of development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company operates under four main segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
At Catalent, innovation and expertise are at the core of their operations. The company is dedicated to accelerating the development and delivery of new treatments by leveraging its advanced technologies and extensive industry knowledge. Catalent's services span the entire lifecycle of a product, from initial drug development and clinical trials to commercial manufacturing and packaging. This end-to-end approach allows them to support pharmaceutical customers with long-term supply agreements and partnerships.
One of Catalent's key strengths lies in its global presence. The company operates over 50 state-of-the-art facilities across four continents, ensuring that it can meet the diverse needs of its clients worldwide. By providing tailored solutions and maintaining high standards of quality and reliability, Catalent has established itself as a trusted partner for many of the world's leading pharmaceutical companies.
Catalent's commitment to innovation is evident through its focus on drug delivery technologies. As a world leader in this field, the company has a proven track record of enhancing bioavailability, solubility, and permeability of drug compounds. These advancements not only improve the efficacy of treatments but also enhance patient compliance and outcomes. Catalent's expertise in developing more effective and convenient drug delivery methods has made a significant impact on the healthcare industry.
Financially, Catalent remains robust, with consistent revenue generation driven by its long-term contracts and diverse service offerings. The company's ability to adapt to market demands and invest in cutting-edge technologies has positioned it for sustained growth. Recent achievements include the expansion of their biologics capabilities and strategic collaborations with key industry players to advance cell and gene therapies.
In conclusion, Catalent, Inc. stands as a pivotal entity in the pharmaceutical and biotechnology sectors. Through their extensive range of services, global reach, and unwavering commitment to innovation, they continue to drive faster, more efficient development timelines and deliver superior manufacturing and packaging solutions. For investors and stakeholders, Catalent represents a vital player in the advancement of modern medicine and healthcare.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Catalent, a global leader in advanced delivery technologies, announced its executive team will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 7:30 a.m. ET. A live webcast of the presentation can be accessed on their investor website and will be available for replay afterward.
With over 17,000 employees and $4 billion in revenue for fiscal 2021, Catalent supports over 1,000 partner programs annually, optimizing product development and supply for the biopharma and consumer health industries.
Edenbridge Pharmaceuticals has received FDA approval for DARTISLA ODT, its first 505(b)(2) branded drug. This orally disintegrating tablet, containing 1.7 mg of glycopyrrolate, is indicated for adults to alleviate peptic ulcer symptoms. DARTISLA ODT is notable as the first and only orally disintegrating tablet formulation of glycopyrrolate. The product is set to launch in early 2022, marking a significant milestone for Edenbridge as it expands into the branded specialty prescription market.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership will present virtually at the Stephens Annual Investment Conference on November 29, 2021 at 11:00 a.m. ET. A live webcast will be available at investor.catalent.com and can be replayed post-event. Catalent is a leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, generating $4 billion in revenue in fiscal 2021 with over 17,000 employees across 50 global sites.
Catalent, Inc. (CTLT) reported Q1'22 net revenue of $1.03 billion, up 21% year-over-year, reflecting 23% organic growth. Net earnings for the quarter reached $93 million with an Adjusted EBITDA of $252 million, marking a 44% increase. The company also acquired Bettera for $1 billion, enhancing its position in the nutritional supplements market. Catalent raised its fiscal 2022 guidance, projecting net revenue of $4.62 billion to $4.82 billion and Adjusted EBITDA of $1.225 billion to $1.295 billion.
Catalent, Inc. (NYSE: CTLT) will announce its first-quarter fiscal results for 2022 on November 2, 2021, before the market opens. A live webcast is scheduled for 8:15 a.m. ET to discuss these results. The supplemental slides will be available in the 'Investors' section of Catalent’s website prior to the webcast. With a workforce of over 17,000 and nearly 90 years in the industry, Catalent reported $4 billion in annual revenue during fiscal year 2021, establishing itself as a leader in developing manufacturing platforms for medicines.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $650 million in senior unsecured notes due 2030, increasing the offering size by $200 million. The proceeds will finance the acquisition of Bettera Holdings, LLC and cover related costs. The notes will be guaranteed by U.S. subsidiaries of Catalent Pharma Solutions but not by Catalent itself. The offering is exempt from SEC registration requirements under Rule 144A and Regulation S and is expected to close on September 29, 2021.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $450 million in senior unsecured notes due 2030 through its subsidiary, Catalent Pharma Solutions. The proceeds will finance part of the acquisition of Bettera Holdings and cover related expenses. The notes will be available to qualified institutional buyers and certain non-U.S. investors. They will not be guaranteed by Catalent or its parent companies. The offering is not registered under the Securities Act, and there are no assurances that either the offering or the acquisition will be completed successfully.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership will present virtually at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 1:15 a.m. ET. A live webcast of the presentation will be available for viewing at investor.catalent.com and can be replayed afterwards. Catalent is a global leader in development sciences and manufacturing for medicines, boasting nearly 90 years in the industry, 17,000 employees, and $4 billion in fiscal year 2021 revenue.
Highlander Partners announced that Catalent will acquire its portfolio company, Bettera Holdings, for $1 billion. Bettera, headquartered in Plano, Texas, is a top manufacturer of gummy vitamins and supplements, operating four facilities in California, Virginia, New Jersey, and Indiana. Highlander formed Bettera through four acquisitions since 2017. The acquisition aims to enhance Catalent's consumer health business, leveraging the growing demand for gummy and lozenge formats. The deal is expected to close by the end of 2021, subject to customary conditions.
FAQ
What is the current stock price of CATALENT (CTLT)?
What is the market cap of CATALENT (CTLT)?
What is Catalent, Inc.'s core business?
How many facilities does Catalent operate?
What segments does Catalent operate under?
What is Catalent known for in drug delivery technologies?
Who are Catalent's primary customers?
What recent achievements has Catalent made?
How does Catalent support drug development?
What distinguishes Catalent in the pharmaceutical industry?
What is the significance of Catalent's global presence?
How does Catalent ensure the quality of their services?
